spline functions to describe non-linear effect (Hastie and Tibshirani, 1995) . The number of knots of each predictor was determined by first fitting several simple logistic regression models which differ from each other by the number of knots (from 0 to 4) and then choosing the number of knots which optimizes the Akaike information criterion (AIC).
A sensitivity analysis was performed with a reduced logistic regession model to address the problem of over-as well as underestimation of regression coefficients due to too many variables per outcome event (Harrell et al., 1984; Peduzzi et al., 1996) and related to this, the problem of overfitting. A backward stepwise variable selection procedure with AIC as stop criteria was carried out on the condition that zoledronate treatment was kept in each selection step resulting in a reduced logistic regression model with zoledronate treatment and "the most important" predictors of the full model. As above, the Wald test was performed and adjusted ORs were estimated. The performance of the logistic regression models was measured with the area under the receiver operator curve (AUC) and the Hosmer-Lemeshow χ2 test, where frequencies of predicted events were compared with frequencies of observed events. A large p-value indicates a satisfactory calibration. Model building was evaluated by 10-fold cross-validation with 50 repetitions to measure the amount of over-fitting. For this purpose, the model building process (i.e., determination of degrees of freedom for continuous predictors, the estimation of regression coefficients, variable selections) was done on each training set resulting in a logistic regression model, which was used then to calculate the AUC on the corresponding validation data set. The average of all these AUCs was taken as evaluation measure. All of the tests were two-sided, and a P value of < 0.05 was regarded as statistically significant. Calculations were carried out using the R system for statistical computing (version 3.0.1; R Development Core Team, Vienna, Austria, 2013)
Results

Patient and tumour characteristics
Data on CTC status at 5 years after primary diagnosis were available for 728 (19.4%) out of 3754 randomized patients. 65 patients (8.9%) had CTCs at five years after diagnosis and 663 (91.1%) had no CTCs. 310 patients had been randomized to 2 years of zoledronate treatment and 418 patients had been randomized to 5 years of zoledronate treatment. 93.8% of all patients had complete observations in all patients and tumour characteristics but CTCs at 2 years after diagnosis which was not considered for statistical analyses. The percentage of missing values in each predictor variable was below 0.5% except for HER2neu (1.8%) and CTC before chemo therapy (4.4%). The missing values of predictor variables were imputed as described above. 19.2% of all patients had no information about CTCs at 2 years after diagnosis. Patient and tumour characteristics according to CTC prevalence at 5 years after diagnosis are shown in Table 1 .
Zoledronic acid treatment and prevalence of CTCs at 5 years
We could not show that the duration of zoledronate treatment (2 or 5 years) influenced the prevalence of CTCs at 5 years after diagnosis (p = 0.13, Wald test). The adjusted OR for 2 years vs 5 years of treatment was 0.65 (95% CI: 0.37 to 1.13). The ORs for the predictors of the full logistic regression analysis is shown in Table 2 . The reduced logistic regression model confirmed the main analysis. The adjusted OR and the p-value of the Wald test were exactly the same as above. ORs are shown in Table 3 Model performance and evaluation The full logistic regression model seemed to be bad calibrated, whereas the calibration of the reduced model seemed to be rather good. Both models seemed to be over-fitted to a certain degree, because the cross-validated AUCs are lower than the apparent AUCs on the original data.
Conclusions
We could not show an influence of zoledronate treatment duration on the prevalence of CTCs five years after primary diagnosis. Other trials in this setting might provide additional information on the predictive role of CTCs in the context of bisphosphonate treatment. 
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